NCT02446652 2025-05-29
Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer
National Institute of Cancerología
Phase 3 Withdrawn
National Institute of Cancerología
Fujian Cancer Hospital
Fujian Cancer Hospital
Medical Research Council